A clinical review of psychoactive drugs and driving emphasizes the exposure pattern as well as the medicine name.
The article discusses benzodiazepines among medicines associated with crash risk and impaired driving. It distinguishes erratic sedative use from stable regimens and emphasizes accompanying substances, medical conditions, and functional assessment. This is a clinical review rather than a new experimental driving trial.
Stable use is not a guarantee of unimpaired performance, and prescribed use does not establish fitness to drive. The review’s discussion of roadside testing also reflects its Australian setting and 2019 publication context.
A medication list does not establish timing, recent escalation, missed doses, or concurrent alcohol. Those details can change the relevant clinical question. Retain observed driving behavior and specimen information alongside the treatment history.
The paper supports an individualized assessment rather than a universal concentration threshold. Its historical testing and legal discussion should not be presented as current law or transferred to another jurisdiction without the relevant legal source.
Original analysis of the supplied journal article, identified as PMC6954869.